Acuta Capital Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Acuta Capital Partners’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-107,500	Closed	-$1.92M	–	35
2019 Q4	$1.92M	Buy	107,500 +82,500	+330%	+$1.08M	0.47%	31
2019 Q3	$290K	Sell	25,000 -188,000	-88%	-$3.04M	0.21%	29
2019 Q2	$4.72M	Buy	213,000 +7,500	+4%	+$176K	1.68%	21
2019 Q1	$5.88M	Buy	205,500 +32,500	+19%	+$705K	2.8%	13
2018 Q4	$3.42M	Buy	173,000 +44,156	+34%	+$888K	2.61%	13
2018 Q3	$2.85M	Buy	+128,844	New	+$1.74M	1.02%	22

Other funds holding KALV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Acuta Capital Partners's KALV Position: Q1 2020 in Review

Acuta Capital Partners sold out of KalVista Pharmaceuticals (KALV) in Q1 2020, closing a stake of 107,500 shares — an estimated $1.92M sold.

Acuta Capital Partners first reported a position in KALV in Q3 2018 and held it in 6 quarters. The position peaked at $5.88M in Q1 2019. 69 funds tracked by Wall St. Rank hold KALV as of Q1 2020.

Acuta Capital Partners reported no remaining KalVista Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Acuta Capital Partners sold 107,500 KalVista Pharmaceuticals shares in Q1 2020, an estimated $1.92M.
Acuta Capital Partners first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 6 quarters.
Acuta Capital Partners's KalVista Pharmaceuticals position peaked at $5.88M in Q1 2019.
69 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2020.

Based on Acuta Capital Partners's 13F filing for Q1 2020, filed 15 May 2020.